[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Ionis Pharmaceuticals (IONS) reports a proposed sale of common stock. The broker listed is Stifel Nicolaus & Company. The notice covers 203,814 shares with an aggregate market value of $12,230,307, to be sold approximately on 09/03/2025 on Nasdaq. The filer shows prior option-exercise acquisitions: 101,489 shares on 01/03/2022, 42,030 shares on 01/03/2023 and 102,900 shares on 01/01/2019, with payment in cash. Two small open-market sales by Brett Monia in July 2025 are also disclosed.

Positive

• None.

Negative

• Proposed insider sale valued at $12,230,307 (203,814 shares) which may be viewed negatively by some investors
• Recent open-market sales in July 2025 (2,432 and 1,160 shares) indicate prior insider dispositions

Insights

Securities Analyst

TL;DR: Insider plans to sell 203,814 shares (~$12.2M) via a broker; appears to be planned, not an emergency disposition.

The filing documents a Rule 144 notice for a planned sale through Stifel Nicolaus of 203,814 common shares valued at $12,230,307, with the approximate sale date listed as 09/03/2025. The shares were acquired through option exercises in 2019, 2022 and 2023 and payment is indicated as cash, consistent with routine post-exercise dispositions. Two small open-market sales in July 2025 (2,432 and 1,160 shares) are also disclosed. The size of the proposed sale should be evaluated relative to the holder's total position and company float; the filing alone does not indicate company performance or undisclosed material information.

Corporate Governance Expert

TL;DR: The notice reflects standard insider selling under Rule 144; disclosure appears complete for the proposed transactions.

The filer certifies no undisclosed material adverse information and lists the relevant acquisition dates and transaction types (option exercises). Use of a broker and the Rule 144 notice indicates an attempt to comply with resale restrictions. Recent small sales in July 2025 are noted, suggesting prior partial dispositions. The filing does not show any regulatory or governance red flags by itself but does constitute insider share movement that investors may monitor.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	203814	12230307.00	159391229	09/03/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/03/2022	Option Exercise	Issuer			101489	09/03/2025	Cash
Common Stock	01/03/2023	Option Exercise	Issuer			42030	09/03/2025	Cash
Common Stock	01/01/2019	Option Exercise	Issuer			102900	09/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brett Monia 2855 Gazelle Ct Carlsbad CA 92010	Common Stock	07/30/2025	2432	109440.00
Brett Monia 2855 Gazelle Ct Carlsbad MO 92010	Common Stock	07/11/2025	1160	48416.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Ionis Pharmaceuticals (IONS) disclose?

The Form 144 discloses a proposed sale of 203,814 common shares valued at $12,230,307, to be sold approximately on 09/03/2025 through Stifel Nicolaus on Nasdaq.

How were the shares being offered on Form 144 acquired?

The disclosed shares were acquired via option exercises on 01/01/2019 (102,900 shares), 01/03/2022 (101,489 shares), and 01/03/2023 (42,030 shares); payment is listed as cash.

Were there any recent sales by the same person prior to this Form 144?

Yes. The filing reports two open-market sales by Brett Monia in July 2025: 2,432 shares on 07/30/2025 for $109,440 and 1,160 shares on 07/11/2025 for $48,416.

Which broker is handling the proposed sale listed on the Form 144?

Stifel Nicolaus & Company Inc., 501 N Broadway, St. Louis, MO 63102, is listed as the broker.

Does the Form 144 state whether the seller knows any material non-public information?

The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.